VanEck Biotech ETF (NASDAQ:BBH) Shares Sold by Aspiriant LLC

Aspiriant LLC reduced its holdings in VanEck Biotech ETF (NASDAQ:BBH) by 40.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,408 shares of the company’s stock after selling 2,955 shares during the quarter. Aspiriant LLC owned about 0.16% of VanEck Biotech ETF worth $733,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of BBH. Focus Financial Network Inc. ADV acquired a new stake in shares of VanEck Biotech ETF in the 4th quarter valued at approximately $2,328,000. Corient Private Wealth LLC acquired a new position in VanEck Biotech ETF during the fourth quarter worth $1,065,000. Raymond James Financial Services Advisors Inc. raised its holdings in VanEck Biotech ETF by 34.5% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 19,129 shares of the company’s stock worth $3,162,000 after purchasing an additional 4,909 shares during the last quarter. Condor Capital Management acquired a new position in VanEck Biotech ETF during the fourth quarter worth $800,000. Finally, CIBC Private Wealth Group LLC acquired a new position in VanEck Biotech ETF during the fourth quarter worth $572,000. 32.05% of the stock is owned by institutional investors and hedge funds.

VanEck Biotech ETF Stock Down 0.1 %

Shares of BBH stock opened at $170.01 on Friday. VanEck Biotech ETF has a 1 year low of $142.51 and a 1 year high of $173.49. The stock has a fifty day moving average price of $164.85 and a 200 day moving average price of $164.35.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.